This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A. PAGE HARRIS, M.D.; HARRIS D. RILEY, Jr., M.D.; VERNON KNIGHT, M.D.

AMA Arch Intern Med. 1957;100(5):701-708.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recently a new sulfonamide compound, sulfamethoxypyridazine, has been introduced into clinical usage which differs in several respects from currently available preparations of this group of drugs.¹ The new agent is promptly absorbed after oral administration, and the free form of the drug is very slowly excreted in the urine. This results in long-sustained high plasma concentrations of free drug with doses much lower than those required to attain similar concentrations with several other sulfonamide agents.

An important area of usage of sulfonamides is in the treatment of urinary tract infections. When they are employed for this purpose, some observers have stressed the value of high urinary concentrations of biologically active material, and this is a prominent characteristic of several sulfonamide derivatives currently available. With sulfamethoxypyridazine, however, urinary concentrations of free drug are low, often not exceeding the plasma concentration. to establish its clinical effectiveness, partic- Thus, while there are apparent . . . [Full Text PDF of this Article]

Author Affiliations
Nashville, Tenn.

From the Departments of Surgery (Urology) (Dr. Harris), Pediatrics (Dr. Riley), and Medicine (Dr. Knight), Vanderbilt University School of Medicine.

Footnotes
Submitted for publication June 4, 1957.

Read in the Symposium on Urinary Tract Infection before the Section on Experimental Medicine and Therapeutics at the 106th Annual Meeting of the American Medical Association, New York, June 4, 1957.

Supported by grants from Lederle Laboratories Division, American Cyanamid Company, Pearl River, N. Y.; the National Foundation for Infantile Paralysis, New York, and the George Hunter Laboratory, Vanderbilt University Medical School.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?